ETFIQData as of Nov 18, 2026. · etfiq.com/funds/xbiDownload PDF

XBI Fact Sheet: State Street SPDR S&P Biotech ETF

Share
$140.18
close, Nov 20, 2026

Over the year to Nov 18, 2026, XBI returned +26.5% in total and charged 0.35% a year.

1-year total return
+23.7%
to Nov 20, 2026
Expense ratio
0.35%
a year
Net assets
$9.6bn
on Nov 19, 2026
Net flow, last 5 trading days
−$303m
daily basis to Nov 19, 2026

Growth of $10,000, 1 year

XBI $12,645 +26.5% · IVV $11,186 +11.9% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.

Returns

WindowTotal return
1 month−8.2%
3 months−15.4%
Year to date+15.1%
1 year+23.7%
3 years+95.9%
5 years+15.7%

Total return, distributions reinvested, each window to Nov 20, 2026.

Ten largest positions

HoldingWeight
MODERNA INC2.31%
TG THERAPEUTICS INC1.87%
BIOGEN INC1.84%
GILEAD SCIENCES INC1.80%
REGENERON PHARMACEUTICALS1.79%
EXELIXIS INC1.77%
ABBVIE INC1.77%
SPYRE THERAPEUTICS INC1.76%
INSMED INC1.76%
AMGEN INC1.75%

XBI top ten by weight, 18.4% of the fund, of its 165 equity positions, from the holdings published by its issuer for Nov 19, 2026.

Facts

Holds 165 stocks in biotech, 14% of its weight in S&P 500 companies · First traded Feb 6, 2006 · Benchmark Its own holdings, as of Nov 19, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, XBI Fact Sheet: State Street SPDR S&P Biotech ETF. Data as of Nov 18, 2026. https://etfiq.com/funds/xbi/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/xbi.